NEJMJClub
Assessing Multiple Treatment Regimens for Tuberculosis.
New England Journal of Medicine · · Journal Article
Esmail, Paton + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Two four-drug regimens for rifampin-susceptible pulmonary tuberculosis—ganfeborole-bedaquiline-pretomanid-moxifloxacin and BTZ-043-bedaquiline-delamanid-moxifloxacin—showed higher log10(time-to-positivity) slopes than HRZE.
- Why it matters: Better regimens are needed to improve tuberculosis treatment while maintaining acceptable tolerability, and this trial aimed to identify candidates for further evaluation rather than fully characterize efficacy.
- What they did: In a phase 2 randomized controlled trial, participants received HRZE for 24 weeks, bedaquiline-delamanid-moxifloxacin for 16 weeks, or 10 new four-drug combinations for 16 weeks; the primary endpoint was the log10(time to positivity) slope from baseline to week 12.
- The result: BPMG had a slope of 0.129 log10(days) per week (95% Bayesian credible interval, 0.112 to 0.146) and BDMT 0.142 (0.126 to 0.160) versus HRZE 0.118 (0.105 to 0.131), with posterior superiority probabilities of 0.83 and 0.99; grade 3+ adverse events were 38% (BPMG), 28% (BDMT), and 24% (HRZE).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.